Development of targeted angiogenic medicine

Carmeliet, 2005, Angiogenesis in life, disease and medicine, Nature, 438, 932, 10.1038/nature04478 Kaelin, 2008, Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway, Mol Cell, 30, 393, 10.1016/j.molcel.2008.04.009 Semenza, 1998, Hypoxia-inducible factor 1: master regulator of O2 homeostasis, Curr Opin Genet Dev, 8, 588, 10.1016/S0959-437X(98)80016-6 Berra, 2006, The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling, EMBO Rep, 7, 41, 10.1038/sj.embor.7400598 Mahon, 2001, FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity, Genes Dev, 15, 2675, 10.1101/gad.924501 Appelhoff, 2004, Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor, J Biol Chem, 279, 38458, 10.1074/jbc.M406026200 Huang, 2002, Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3, J Biol Chem, 277, 39792, 10.1074/jbc.M206955200 Koivunen, 2007, An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha, J Biol Chem, 282, 30544, 10.1074/jbc.M704988200 Maxwell, 1999, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature, 399, 271, 10.1038/20459 Fong, 2008, Role and regulation of prolyl hydroxylase domain proteins, Cell Death Differ, 15, 635, 10.1038/cdd.2008.10 Compernolle, 2002, Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice, Nat Med, 8, 702, 10.1038/nm721 Compernolle, 2003, Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha, Cardiovasc Res, 60, 569, 10.1016/j.cardiores.2003.07.003 Patel, 2008, Biology of hypoxia-inducible factor-2alpha in development and disease, Cell Death Differ, 15, 628, 10.1038/cdd.2008.17 Semenza, 2004, O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1, J Appl Physiol, 96, 1173, 10.1152/japplphysiol.00770.2003 Semenza, 2003, Targeting HIF-1 for cancer therapy, Nat Rev Cancer, 3, 721, 10.1038/nrc1187 Kelly, 2003, Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1, Circ Res, 93, 1074, 10.1161/01.RES.0000102937.50486.1B Hirota, 2006, Regulation of angiogenesis by hypoxia-inducible factor 1, Crit Rev Oncol Hematol, 59, 15, 10.1016/j.critrevonc.2005.12.003 Maulik, 2008, Growth factors and cell therapy in myocardial regeneration, J Mol Cell Cardiol, 44, 219, 10.1016/j.yjmcc.2007.11.012 Milkiewicz, 2004, Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice, J Physiol, 560, 21, 10.1113/jphysiol.2004.069757 Patel, 2005, Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia, Cardiovasc Res, 68, 144, 10.1016/j.cardiores.2005.05.002 Vincent, 2000, Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor, Circulation, 102, 2255, 10.1161/01.CIR.102.18.2255 Jiang, 2008, Angiogenesis by transplantation of HIF-1 alpha modified EPCs into ischemic limbs, J Cell Biochem, 103, 321, 10.1002/jcb.21416 Li, 2000, PR39, a peptide regulator of angiogenesis, Nat Med, 6, 49, 10.1038/71527 Heinl-Green, 2005, The efficacy of a ‘master switch gene’ HIF-1alpha in a porcine model of chronic myocardial ischaemia, Eur Heart J, 26, 1327, 10.1093/eurheartj/ehi223 Anan, 2006, Induced angiogenesis under cerebral ischemia by cyclooxygenase 2 and hypoxia-inducible factor naked DNA in a rat indirect-bypass model, Neurosci Lett, 409, 118, 10.1016/j.neulet.2006.09.039 Matsuda, 2005, Hypoxia-inducible factor-1alpha DNA induced angiogenesis in a rat cerebral ischemia model, Neurol Res, 27, 503, 10.1179/016164105X25144 Rajagopalan, 2007, Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience, Circulation, 115, 1234, 10.1161/CIRCULATIONAHA.106.607994 Takeda, 2006, Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2, Mol Cell Biol, 26, 8336, 10.1128/MCB.00425-06 Takeda, 2007, Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system, Circulation, 116, 774, 10.1161/CIRCULATIONAHA.107.701516 Takeda, 2008, Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins, Blood, 111, 3229, 10.1182/blood-2007-09-114561 Minamishima, 2008, Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure, Blood, 111, 3236, 10.1182/blood-2007-10-117812 Willam, 2006, HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation, J Mol Cell Cardiol, 41, 68, 10.1016/j.yjmcc.2006.04.009 Rohrbach, 2005, Age-dependent increase of prolyl-4-hydroxylase domain (PHD) 3 expression in human and mouse heart, Biogerontology, 6, 165, 10.1007/s10522-005-7950-9 Cioffi, 2003, Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells, Biochem Biophys Res Commun, 303, 947, 10.1016/S0006-291X(03)00453-4 Rohrbach, 2008, Caloric restriction counteracts age-dependent changes in prolyl-4-hydroxylase domain (PHD) 3 expression, Biogerontology, 9, 169, 10.1007/s10522-008-9126-x Schlisio, 2008, The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor, Genes Dev, 22, 884, 10.1101/gad.1648608 Rantanen, 2008, Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation, Mol Biol Cell, 19, 2231, 10.1091/mbc.e07-11-1124 Bishop, 2008, Abnormal sympathoadrenal development and systemic hypotension in PHD3−/− mice, Mol Cell Biol, 28, 3386, 10.1128/MCB.02041-07 Siddiq, 2007, Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress, Neurochem Res, 32, 931, 10.1007/s11064-006-9268-7 Tegley, 2008, Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation, Bioorg Med Chem Lett, 18, 3925, 10.1016/j.bmcl.2008.06.031 Nangaku, 2007, A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia, Arterioscler Thromb Vasc Biol, 27, 2548, 10.1161/ATVBAHA.107.148551 Wu, 2008, Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene, Mol Ther, 16, 1227, 10.1038/mt.2008.90 Rankin, 2008, The role of hypoxia-inducible factors in tumorigenesis, Cell Death Differ, 15, 678, 10.1038/cdd.2008.21 Carmeliet, 1998, Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis, Nature, 394, 485, 10.1038/28867 Acker, 2005, Genetic evidence for a tumor suppressor role of HIF-2alpha, Cancer Cell, 8, 131, 10.1016/j.ccr.2005.07.003 Semenza, 2007, Evaluation of HIF-1 inhibitors as anticancer agents, Drug Discov Today, 12, 853, 10.1016/j.drudis.2007.08.006 Paul, 2004, HIF at the crossroads between ischemia and carcinogenesis, J Cell Physiol, 200, 20, 10.1002/jcp.10479 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Lee, 2007, Autocrine VEGF signaling is required for vascular homeostasis, Cell, 130, 691, 10.1016/j.cell.2007.06.054 Carmeliet, 1996, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature, 380, 435, 10.1038/380435a0 Ferrara, 1996, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature, 380, 439, 10.1038/380439a0 Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669 Dvorak, 1995, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, Am J Pathol, 146, 1029 Yang, 1996, Effects of vascular endothelial growth factor on hemodynamics and cardiac performance, J Cardiovasc Pharmacol, 27, 838, 10.1097/00005344-199606000-00011 Shima, 1996, The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences, J Biol Chem, 271, 3877, 10.1074/jbc.271.7.3877 Carmeliet, 1999, Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188, Nat Med, 5, 495, 10.1038/8379 Maes, 2002, Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188, Mech Dev, 111, 61, 10.1016/S0925-4773(01)00601-3 Stalmans, 2002, Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms, J Clin Invest, 109, 327, 10.1172/JCI0214362 Mattot, 2002, Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice, J Am Soc Nephrol, 13, 1548, 10.1097/01.ASN.0000013925.19218.7B Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005 Jain, 2006, Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nat Clin Pract Oncol, 3, 24, 10.1038/ncponc0403 Kramer, 2007, Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer, J Clin Pharm Ther, 32, 1, 10.1111/j.1365-2710.2007.00800.x Noel, 2007, Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts, Trends Mol Med, 13, 345, 10.1016/j.molmed.2007.06.005 Rosenfeld, 2006, Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, 1419, 10.1056/NEJMoa054481 Gragoudas, 2004, Pegaptanib for neovascular age-related macular degeneration, N Engl J Med, 351, 2805, 10.1056/NEJMoa042760 Pieramici, 2008, Anti-VEGF therapy: comparison of current and future agents, Eye, 22, 1330, 10.1038/eye.2008.88 Rosenfeld, 2006, Ranibizumab: Phase III clinical trial results, Ophthalmol Clin North Am, 19, 361 Autiero, 2003, Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1, Nat Med, 9, 936, 10.1038/nm884 Park, 1994, Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR, J Biol Chem, 269, 25646, 10.1016/S0021-9258(18)47298-5 Clauss, 1996, The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis, J Biol Chem, 271, 17629, 10.1074/jbc.271.30.17629 Fischer, 2007, Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels, Cell, 131, 463, 10.1016/j.cell.2007.08.038 Hattori, 2002, Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment, Nat Med, 8, 841, 10.1038/nm740 Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186 Rosen, 2007, Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors, J Clin Oncol, 25, 2369, 10.1200/JCO.2006.07.8170 Willett, 2005, Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients, J Clin Oncol, 23, 8136, 10.1200/JCO.2005.02.5635 Taylor, 2003, Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence, Int J Cancer, 105, 158, 10.1002/ijc.11059 Carmeliet, 2001, Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions, Nat Med, 7, 575, 10.1038/87904 Luttun, 2002, Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1, Nat Med, 8, 831, 10.1038/nm731 Li, 2008, Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium, Arterioscler Thromb Vasc Biol, 28, 1614, 10.1161/ATVBAHA.107.158725 Roncal, 2008, Beneficial effects of prolonged systemic administration of PlGF on late outcome of post-ischemic myocardial performance, J Pathol, 216, 236, 10.1002/path.2408 Tirziu, 2007, Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice, J Clin Invest, 117, 3188, 10.1172/JCI32024 Iwasaki, 2006, Novel therapeutic mechanism of placental growth factor in myocardial infarction: Tissue repair through enhancement of proliferation, mobilization abd recruitment of cardiac stem cells for cardiac myoangiogenesis, Circulation, 114 Shiojima, 2005, Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure, J Clin Invest, 115, 2108, 10.1172/JCI24682 Schwartz, 2006, The politics and promise of stem-cell research, N Engl J Med, 355, 1189, 10.1056/NEJMp068180 Kim, 2006, HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia, Cell Metab, 3, 177, 10.1016/j.cmet.2006.02.002 Fukuda, 2007, HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells, Cell, 129, 111, 10.1016/j.cell.2007.01.047 Papandreou, 2006, HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption, Cell Metab, 3, 187, 10.1016/j.cmet.2006.01.012 Kim, 2007, Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1, Mol Cell Biol, 27, 7381, 10.1128/MCB.00440-07 Zhang, 2007, HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity, Cancer Cell, 11, 407, 10.1016/j.ccr.2007.04.001 Aragones, 2008, Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism, Nat Genet, 40, 170, 10.1038/ng.2007.62 Zacchigna, 2008, Neurovascular signalling defects in neurodegeneration, Nat Rev Neurosci, 9, 169, 10.1038/nrn2336 Carmeliet, 2003, Blood vessels and nerves: common signals, pathways and diseases, Nat Rev Genet, 4, 710, 10.1038/nrg1158 Carmeliet, 2005, Common mechanisms of nerve and blood vessel wiring, Nature, 436, 193, 10.1038/nature03875 Oosthuyse, 2001, Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration, Nat Genet, 28, 131, 10.1038/88842 Lambrechts, 2003, VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death, Nat Genet, 34, 383, 10.1038/ng1211 Lambrechts, 2008, Meta-analysis of VEGF variations in ALS: increased susceptibility in male carriers of the -2578AA genotype, J Med Genet Azzouz, 2004, VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model, Nature, 429, 413, 10.1038/nature02544 Storkebaum, 2005, Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS, Nat Neurosci, 8, 85, 10.1038/nn1360